Global Human Micobiome Market Size, Status and Forecast 2019-2025
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The research usually can last 8-10 years, so scale production will occur in 2018. Before then, the Human Micobiome companies have to continue deficit.
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
In 2018, the global Human Micobiome market size was 170 million US$ and it is expected to reach 820 million US$ by the end of 2025, with a CAGR of 21.7% during 2019-2025.
This report focuses on the global Human Micobiome status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Micobiome development in United States, Europe and China.
The key players covered in this study
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Market segment by Type, the product can be split into
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Other
Market segment by Application, split into
Treatment
Diagnosis
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Human Micobiome status, future forecast, growth opportunity, key market and key players.
To present the Human Micobiome development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Human Micobiome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The research usually can last 8-10 years, so scale production will occur in 2018. Before then, the Human Micobiome companies have to continue deficit.
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
In 2018, the global Human Micobiome market size was 170 million US$ and it is expected to reach 820 million US$ by the end of 2025, with a CAGR of 21.7% during 2019-2025.
This report focuses on the global Human Micobiome status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Micobiome development in United States, Europe and China.
The key players covered in this study
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Market segment by Type, the product can be split into
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Other
Market segment by Application, split into
Treatment
Diagnosis
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Human Micobiome status, future forecast, growth opportunity, key market and key players.
To present the Human Micobiome development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Human Micobiome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
